Clinical trial
Open-Label Phase III Long-Term Safety Trial of Liprotamase
NCT00449904 · Anthera Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00449904 |
|---|---|
| Title | Open-Label Phase III Long-Term Safety Trial of Liprotamase |
| Official title | An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency |
| Acronym | DIGEST |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Exocrine Pancreatic Insufficiency |
| Intervention type | Drug |
| Interventions | Liprotamase |
| Enrollment | 214 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Mar 21, 2007 |
| Last update posted | Oct 24, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: